IC₅₀s data of antimalarials against controls. by Winnie Okore (14139712)

Drugs IC₅₀s data during the study period. by Winnie Okore (14139712)

SNPs IC₅₀s data at codon 876 during the study period. by Winnie Okore (14139712)

Association of polymorphic IC_50s versus wild<i>-</i>type at codon 876 in selected drugs tested. by Winnie Okore (14139712)

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…Compound <b>4f</b> exhibited potent EGFR inhibitory activity with an IC₅₀ value of 61 nM compared to that of Tamoxifen (IC₅₀ value of 69 nM), with EGFR inhibition of 83 and 84%, respectively, at a concentration of 10 μM. …”

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…Compound <b>4f</b> exhibited potent EGFR inhibitory activity with an IC₅₀ value of 61 nM compared to that of Tamoxifen (IC₅₀ value of 69 nM), with EGFR inhibition of 83 and 84%, respectively, at a concentration of 10 μM. …”

Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. by Narendran Gopalan (110148)

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

Excision of HIF1α decreases viral reactivation from latency in infected splenocytes in vivo. by Darlah M. López-Rodríguez (8098544)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

Performance of selected antimalarials against field isolates during the study period. by Winnie Okore (14139712)

Number of samples per site during the study period. by Winnie Okore (14139712)

Performance of selected drugs against field isolates during the study period. by Winnie Okore (14139712)

<i>In vitro</i> susceptibility responses of field isolates to antimalarials during the study period. by Winnie Okore (14139712)